Advertisement

Kolorektales Karzinom

  • G. H. Blijham

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer Statistics. CA Cancer J Clin 47:5–27PubMedCrossRefGoogle Scholar
  2. 2.
    Trock B, Lanza E, Greenwald P (1990) Dietary fiber, vegetables and colon cancer. critical review and meta-analysis of the epidemiologic evidence. J Natl Cancer Inst 82:650–661PubMedCrossRefGoogle Scholar
  3. 3.
    Willett WC, Stamfer MJ, Colditz G et al. (1990) Relation of meat, fat, and fibe intake to the risk of colon cancer in a prospective study among women. N Engl J Med 323:1664–1672PubMedCrossRefGoogle Scholar
  4. 4.
    Giovannucci E, Stampfer MJ, Colditz G et al. (1992) Relationship of diet to risk of colorectal adenoma in mem. J Natl Cancer Inst 84:91–98PubMedCrossRefGoogle Scholar
  5. 5.
    Howe GR, Benito E, Castelleto R et al. (1992) Dietary intake of fiber and decreased risk of cancers of the colon and rectum. Evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 84:1887–1896PubMedCrossRefGoogle Scholar
  6. 6.
    Vasen HFA, Mecklin JP, Kahn PM, Lynch HT (1991) Hereditary non-polyposis colorectal cancer. Lancet 338:877CrossRefGoogle Scholar
  7. 7.
    Hamilton SR (1993) The molecular genetics of colorectal neoplasia. Gastroenterology 105:3–7PubMedGoogle Scholar
  8. 8.
    Jessup JM, Menck HR, Fremgen A, Winchester DP (1997) Diagnosing Colorectal Carcinoma: Clinical and Molecular Approaches. CA Cancer J Clin 47:70–92PubMedCrossRefGoogle Scholar
  9. 9.
    Markowitz AJ, Winawer SJ (1997) Management of colorectal polyps. CA Cancer J Clin 47:93–112PubMedCrossRefGoogle Scholar
  10. 10.
    Muto T, Bussey HJR, Morson BC (1975) The evolution of cancer of the colon and rectum. Cancer 36:2270–3351CrossRefGoogle Scholar
  11. 11.
    Stryker SJ, Wolff BG, Culp CE et al. (1987) Natural history of untreated colonic polyps. Gastroenterology 93:1009–1013PubMedGoogle Scholar
  12. 12.
    Winawer SJ, Zauber AG, Ho MN et al. (1993) Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329:1977–1981PubMedCrossRefGoogle Scholar
  13. 13.
    Blenkinsopp WK, Stewart-Brown S, Blesowsky L et al. (1981) Histopathology reporting in large bowel cancer. J Clin Pathol 34:509–513PubMedCrossRefGoogle Scholar
  14. 14.
    Dukes CE (1932) The classification of cancer of the rectum. J Pathol 35:323–332CrossRefGoogle Scholar
  15. 15.
    Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846–851PubMedCrossRefGoogle Scholar
  16. 16.
    TNM-Klassifikation maligner Tumoren, 5. Auflage (1997) In: Wittekind CH, Wagner G (Hrsg), Springer VerlagGoogle Scholar
  17. 17.
    Nathanson SD, Schultz L, Tilley B et al. (1986) Carcinoma of the colon and rectum: A comparison of staging classifications. Ann Surg 52:428–433Google Scholar
  18. 18.
    Jass JR, Mukawa K, Goh HS et al. (1989) Clinical importance of DNA content in rectal cancer measured by flow cytometry. J Clin Pathol 42:254–259PubMedCrossRefGoogle Scholar
  19. 19.
    Witzig TE, Loprinzi CL, Gonchosoff NJ et al. (1991) DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B2 and C colorectal adenocarcinoma. Cancer 68:879–888PubMedCrossRefGoogle Scholar
  20. 20.
    Hamelin R, Laurent-Puig P, Olschwang S et al. (1994) Association of P53 mutations with short survival in colorectal cancer. Gastroenterology 106:42–48PubMedGoogle Scholar
  21. 21.
    Bosari S, Viale G, Bossi P et al. (1994) Cytoplasmatic accumulation of P53 protein: an independent progonstic indicator adenocarcinomas. J Natl Cancer Inst 86:681–687PubMedCrossRefGoogle Scholar
  22. 22.
    Jen J, Kim H, Piantadosi SP et al. (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221PubMedCrossRefGoogle Scholar
  23. 23.
    Willett CG, Tepper JE, Cohen AM et al. (1984) Failure patterns following curative resection of colonic carcinoma. Ann Surg 200:685–690PubMedCrossRefGoogle Scholar
  24. 24.
    Rich T, Gunderson LL, Lew R et al. (1983) Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 52:1317–1329PubMedCrossRefGoogle Scholar
  25. 25.
    Read TE, Read JD, Butterfly LF (1997) Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl J Med 336:8–12PubMedCrossRefGoogle Scholar
  26. 26.
    Rothenberg DA, Buie WD (1994) Local regional staging of rectal cancer. In: Cohen AM, Winawer SJ (eds) Cancer of the Colon, Rectum and Anus. New York, McGraw-Hill, pp 521–531Google Scholar
  27. 26a.
    de Mello J, Struthers L, Turner R et al. (1983) Multivariate analysis as acides to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 48: 341–348PubMedCrossRefGoogle Scholar
  28. 26b.
    Moertel CG, O’Fallon JR, Go VL et al. (1986) The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 58:603–610PubMedCrossRefGoogle Scholar
  29. 26c.
    August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303–324PubMedCrossRefGoogle Scholar
  30. 26a.
    Staab HJ, Anderer FA, Stumpf E et al. (1985) Eighty-four second look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 179: 198–204CrossRefGoogle Scholar
  31. 26e.
    Denstman F, Rosen L, Khubchandani IT et al. (1986) Comparing predictive decision rule in postoperative CEA monitoring. Cancer 58:2089–2095PubMedCrossRefGoogle Scholar
  32. 26f.
    Moertel CG et al. (1993) An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943–947PubMedCrossRefGoogle Scholar
  33. 27.
    Buyse M, Zeleniuch-Jacquotte A, Chalmers TC (1988) Adjuvant therapy of colorectal cancer. J Am Med Assoc 259:3571–3578CrossRefGoogle Scholar
  34. 28.
    Guillem JG (1997) Surgical treatment of colorectal cancer. CA Cancer J Clin 47: 113–128PubMedCrossRefGoogle Scholar
  35. 29.
    Nordlinger BG, Guiguet M, Vaillant J et al. (1996) Surgical resection of colorectal carcinoma metastases to the liver. Cancer 77:1254–1262PubMedCrossRefGoogle Scholar
  36. 30.
    McCormack PM, Burt ME, Bains MS et al. (1992) Lung resection for colorectal metastases: 10-year results. Arch Surg 127:1403–1406PubMedCrossRefGoogle Scholar
  37. 31.
    Blijham GH (1991) Chemotherapy of colorectal cancer. Anti-Cancer Drugs 2:233–245PubMedCrossRefGoogle Scholar
  38. 32.
    Moertel CG (1994) Chemotherapy for Colorectal Cancer. N Engl J Med 330:1136–1142PubMedCrossRefGoogle Scholar
  39. 33.
    Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896–903Google Scholar
  40. 34.
    Advanced Colorectal Cancer Meta-analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960–969Google Scholar
  41. 35.
    Laufmann LR, Bukowski RM, Collier MA et al. (1993) A randomized double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 11:1888–1893Google Scholar
  42. 36.
    Poon MA, O’Connell MJ, Wieand HS et al. (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972PubMedGoogle Scholar
  43. 37.
    Petrelli N, Herrera L, Rustum Y et al. (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluoro-uracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559–1565PubMedGoogle Scholar
  44. 38.
    Valone FH, Friedman MA, Wittlinger PS et al. (1989) Treatment of patients with advanced colorectal carcinoma with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil and leucovorin; a randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427–1436PubMedGoogle Scholar
  45. 39.
    Glimelius B (1993) Biochemical modulation of 5-Fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235–240PubMedGoogle Scholar
  46. 40.
    Buroker TR, O’Connell MJ, Wieand HS et al. (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14–20PubMedGoogle Scholar
  47. 41.
    Labianca R, Cascinu S, Frontini L et al. (1997) High versus low dose levoleucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. Ann Oncol 8:169–174PubMedCrossRefGoogle Scholar
  48. 42.
    Jäger E, Heike M, Bernard H et al. (1996) Weekly high-dose leucovorin versus low-dose, leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 14:2274–2279PubMedGoogle Scholar
  49. 43.
    Scheithauer W, Kornek G, Marczell A et al. (1997) Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III. J Clin Oncol 15:908–914PubMedGoogle Scholar
  50. 44.
    Brook J (1995) Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin. What is the real cost? What is the answer. J Clin Oncol 13 : 1830–1831PubMedGoogle Scholar
  51. 45.
    Poon MA, O’Connell MJ, Moertel CG et al. (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407–1418PubMedGoogle Scholar
  52. 46.
    Wadler S, Schwartz EL, Goldman M et al. (1989) Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal cancer. J Clin Oncol 7:1769–1775PubMedGoogle Scholar
  53. 47.
    Corfu-A study group (1995) Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921–928Google Scholar
  54. 48.
    Hill M, Norman A, Cunningham D et al. (1995) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297–1302PubMedGoogle Scholar
  55. 49.
    Seymour MT, Slevin ML, Kerr D et al. (1996) Randomized trial assessing the addition of interferon alfa-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 14:2280–2288PubMedGoogle Scholar
  56. 50.
    Greco FA, Figlin R, York M et al. (1996) Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674–2681PubMedGoogle Scholar
  57. 51.
    Kosmidis PA, Tsavaris N, Skarlos D et al. (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. J Clin Oncol 14:2682–2687PubMedGoogle Scholar
  58. 52.
    Wils JA (1992) High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Sem Oncol: 19(Suppl 3) : 126–130Google Scholar
  59. 53.
    Sobrero A, Aschele C, Bertino J (1997) Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation. J Clin Oncol 15:368–381PubMedGoogle Scholar
  60. 54.
    Lokich JJ, Ahlgren JD, Gullo JJ et al. (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7:425–432PubMedGoogle Scholar
  61. 55.
    Rougier PH, Paillot B, Laplance A et al. (1992) End results of a multicentric randomized trial comparing 5-FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 11:163Google Scholar
  62. 56.
    De Gramont A, Bosset JF, Milon C et al. (1997) Randomized trial comparing monthly low dose leucovorin and Fluorouracil bolus with bimonthly high-dose leucovorin and Fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French Intergroup Study. J Clin Oncol 15:808–815PubMedGoogle Scholar
  63. 57.
    Blijham GH, Wagener T, Wils J et al. (1996) Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer. Final results of a randomized European Organisation for Research and Treatment of Cancer study. J Clin Oncol 14:2266–2273PubMedGoogle Scholar
  64. 58.
    Aranda E, Cervantes A, Anton A et al. (1997) A phase III multicenter randomized study in advanced colorectal cancer: fluorouracil high dose continuous infusion weekly versus fluorouracil + leucovorin. Preliminary results. Proc Am Soc Clin Oncol 16:281aGoogle Scholar
  65. 59.
    Köhne C, Schöffski P, Wilke H et al. (1997) Biochemical modulation of weekly high-dose infusional (HD-CI) 5-FU in patients with advanced colorectal cancer. Results of a multicenter randomized AIO trial. Proc Am Soc Clin Oncol 16:271 aGoogle Scholar
  66. 60.
    Ross P, Norman A, Cunningham et al. (1997) A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer. Proc Am Soc Clin Oncol 16:271 aGoogle Scholar
  67. 61.
    Rougier P, Buyse M, Ryan L, Hansen R (1997) Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients wieth advanced colorectal cancer. Proc Am Soc Clin Oncol 16:267aGoogle Scholar
  68. 62.
    Ross PF, Webb A, Cunningham D et al. (1997) Infusional 5-fluorouracil in the treatment of gastrointestinal cancer: the Royal Marsden Hospital experience. Ann Oncol: 111–116Google Scholar
  69. 63.
    Leichman CG, Fleming TR, Muggia FM et al. (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncolog Group Study. J Clin Oncol 13:1303–1311PubMedGoogle Scholar
  70. 64.
    Blijham GH, Wagener TH, Wils J et al. (1997) Double modulation of high-dose 5-fluorouracil (FU) with low-dose PALA and methotrexate (MTX): results of a randomized EORTC study. Proc Am Soc Clin Oncol 16:267 aGoogle Scholar
  71. 65.
    Van Cutsem E (1996) A glimpse of the future. New directions in the treatment of colorectal cancer. Eur J Cancer 32 A(Suppl 5) :S 23–27CrossRefGoogle Scholar
  72. 66.
    Bleiberg H (1997) Colorectal cancer. Is there an alternative to 5-FU? Eur J Cancer 33:536–541PubMedCrossRefGoogle Scholar
  73. 67.
    Cunningham D, Zalcberg J, Rath U et al. (1997) Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-Fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961–965CrossRefGoogle Scholar
  74. 68.
    Pazdur R, Vincent M (1997) Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16:228 aGoogle Scholar
  75. 69.
    Harper P (1997) Advanced colorectal cancer (ACC): results from the latest Tomudex® (raltitrexed) comparative study. Proc Am Soc Clin Oncol 16: 228aGoogle Scholar
  76. 70.
    Cripps MC, Burnfeld M, Jolivet J et al. (1997) Phase II study of a multi-targeted antifolate (LY23 1514) (MTA) as first-line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:267aGoogle Scholar
  77. 71.
    Rougier P, Bugat R, Douillard JY et al. (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260PubMedGoogle Scholar
  78. 72.
    Rothenberg ML, Eckhardt JR, Kuhn JG et al. (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128–1135PubMedGoogle Scholar
  79. 73.
    Conti JA, Kemeny N, Saltz L et al. (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715PubMedGoogle Scholar
  80. 74.
    Van Cutsem E, Rougier PH, Doz JP et al. (1997) Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU. Proc Am Soc Clin Oncol 16:268 aGoogle Scholar
  81. 75.
    Abigerges D, Armand JP, Chabot GG et al. (1994) Irinotecan (CPT-11) high-dose escalation using high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446–449PubMedCrossRefGoogle Scholar
  82. 76.
    Malik STA, Talbot D, Clarke PI et al. (1990) Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 62:1023–1025PubMedCrossRefGoogle Scholar
  83. 77.
    Pazdur R, Lassere Y, Rhodes V et al. (1994) Phase II trial of Uracil and Tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296–3000PubMedGoogle Scholar
  84. 78.
    González Barón M, Feliu J, de la Gándara I et al. (1995) Efficacy of oral Tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31:2215–2219CrossRefGoogle Scholar
  85. 79.
    Saltz LB, Leichman CF, Young CW et al. (1995) A fixed-ratio combination of uracil and ftorafur (UFT®) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75:782–785PubMedCrossRefGoogle Scholar
  86. 80.
    Peters GJ, Van Groeningen CJ, Schornagel JH et al. (1997) Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc Am Soc Clin Oncol 15:227 aGoogle Scholar
  87. 81.
    Schildky R, Bukowski R, Burris H et al. (1997) A phase II study of a five day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:171 aGoogle Scholar
  88. 82.
    Findlay M, Van Cutsem E, Kocha W et al. (1997) A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:227aGoogle Scholar
  89. 83.
    Brown TD, Fleming TR, Goodman PJ et al. (1995) A randomized trial of two schedules of trimetrexate versus 5-Fluorouracil in advanced colorectal cancer: a SWOG Study. Anticancer Drugs 6:219–223PubMedCrossRefGoogle Scholar
  90. 84.
    Romanini A, Li WW, Colofiore JR, Bertino JR (1992) Leucovorin enhaces cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Nat Cancer Inst 84:1033–1038PubMedCrossRefGoogle Scholar
  91. 85.
    Conti JA, Kemeny N, Seiter K et al. (1994) Trial of sequential trimetrexate, fluorouracil and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 12:695–700PubMedGoogle Scholar
  92. 86.
    Blanke CD, Kasimis B, Schein P et al. (1997) Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 15:915–920PubMedGoogle Scholar
  93. 87.
    Machover D, Diaz-Rubio E, de Gramont et al. (1996) Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95–98PubMedCrossRefGoogle Scholar
  94. 88.
    Bécouarn Y, Ychou M, Ducreux M et al. (1997) Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 16:229 aGoogle Scholar
  95. 89.
    De Gramont A, Vignoud J, Tournigand C et al. (1997) Oxaliplatin with high-dose leucovorin and 5-Fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214–219PubMedCrossRefGoogle Scholar
  96. 90.
    Lévi F, Zidani R, Vannetzel MJ et al. (1994) Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Inst 86:1608–1617PubMedCrossRefGoogle Scholar
  97. 91.
    Giacchetti S, Zidani R, Perpoint B et al. (1997) Phase III trial of 5-fluorouracil (5-FU) folinic acid (FA, with or without oxaliplatin (OXA) in previously untreated patients (PTS) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:229aGoogle Scholar
  98. 92.
    Bertheault-Cvitkovic F, Jami A, Ithzakin M et al. (1996) Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14:2950–2958PubMedGoogle Scholar
  99. 93.
    Lévi F, Dogliotti L, Perpoint B et al. (1997) A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with previously untreated metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:266aGoogle Scholar
  100. 94.
    Laurie JA, Moertel CG, Fleming TR et al. (1989) Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole and the combination of levamisole and 5-fluorouracil. J Clin Oncol 7:1447–1456PubMedGoogle Scholar
  101. 95.
    Moertel CG, Fleming TR, MacDonald JS et al. (1990) Levamisole and fluorouracil for surgical adjuvant therapy of colon carcinoma. N Engl J Med 322:352–358PubMedCrossRefGoogle Scholar
  102. 96.
    Moertel CG, Fleming TR, MacDonald J et al. (1992) The intergroup study of 5-FU plus lev and levamisole alone as adjuvant therapy for stage C colon cancer: A final report. Proc Am Soc Clin Oncol 11:161Google Scholar
  103. 97.
    Wolmark N, Rockette H, Fisher B et al. (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy of primary colon cancer: Results from the NSABP protocol C-03. J Clin Oncol 11:1879–1887PubMedGoogle Scholar
  104. 98.
    Marsoni S (for the IMPACT investigators) (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944CrossRefGoogle Scholar
  105. 99.
    O’Connell MJ, Mailliard JA, Kahn MJ et al. (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250PubMedGoogle Scholar
  106. 100.
    Francini G, Perioli R, Lorenzini L et al. (1994) Folinic acid and 5-fluorouracil as adjuvant chemotheray in colon cancer. Gastroenterology 106:899–906PubMedGoogle Scholar
  107. 101.
    Moertel CG, Fleming TR, MacDoanld JS et al. (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11:2386–2390PubMedGoogle Scholar
  108. 102.
    Wolmark N, Rockette H, Mamounas EP et al. (1996) The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-Lev) and 5-FU + leucovorin + levamisole (FU-LV-Lev) in patients with Duke’s B and C carcinoma of the colon: first report of NSABP C-04. Proc Am Soc Clin Oncol 15:205Google Scholar
  109. 103.
    Haller DG, Catalano PJ, Macdonald JS et al. (1996 and 1997) Fluorouracil (FU), leucovorin (LV) and levamisole (lev) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc Am Soc Clin Oncol 15:21,Google Scholar
  110. 103a.
    Haller DG, Catalano PJ, Macdonald JS et al. (1996 and 1997) Fluorouracil (FU), leucovorin (LV) and levamisole (lev) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc Am Soc Clin Oncol 16:265aGoogle Scholar
  111. 104.
    O’Connell MJ, Laurie JA, Shepherd L et al. (1996) A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 15:209Google Scholar
  112. 105.
    National Institutes of Health Consensus Development Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450CrossRefGoogle Scholar
  113. 106.
    Taylor I, Machin D, Mullee M et al. (1985) A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 72:359–363PubMedCrossRefGoogle Scholar
  114. 107.
    Wereldsma JCJ, Bruggink EDM, Meyer WS et al. (1990) Adjuvant portal liver infusion in colorectal cancer with 5-Fluorouracil/heparin versus urokinase versus control. Cancer 65:425–432PubMedCrossRefGoogle Scholar
  115. 108.
    Beart RW, Moertel CG, Wieand HS et al. (1990) Adjuvant therapy for resectable colorectal carcinoma with 5-Fluorouracil administered by portal infusion. Arch Surg 125:897–901PubMedCrossRefGoogle Scholar
  116. 109.
    Wolmark N, Rockette H, Wickerham DL et al. (1990) Adjuvant therapy of Dukes’ A, B and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of NSABP protocol C-02. J Clin Oncol 8:1466–1475PubMedGoogle Scholar
  117. 110.
    Wolmark N, Rockette H, Petrelli N et al. (1994) Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer. NSABP C-02. Proc Am Soc Clin Oncol 13:194Google Scholar
  118. 111.
    Metzger U, Laffer U, Castiglione M et al. (1989) Adjuvant intraportal chemotherapy for colorectal cancer. Four year results of the randomized Swiss study. Proc Am Soc Clin Oncol 8:105Google Scholar
  119. 112.
    Fielding LP, Hittinger R, Grace RH et al. (1992) Randomized controlled trial of adjuvant chemotherapy by portal vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 340:502–506PubMedCrossRefGoogle Scholar
  120. 113.
    Piedbois P, Buyse M, Gray I et al. (1995) Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 14:192Google Scholar
  121. 114.
    Crowley JJ (1994) Perioperative portal vein chemotherapy. ASCO Educational Book, pages 171–175Google Scholar
  122. 115.
    Nordic Gastrointestinal Tumor Adjuvant Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10:904–911Google Scholar
  123. 116.
    Scheithauer W, Rosen H, Korneck GV et al. (1993) Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752–755PubMedCrossRefGoogle Scholar
  124. 117.
    Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255–1260PubMedCrossRefGoogle Scholar
  125. 118.
    Hafström L, Engarås B, Holmberg ST et al. (1994) Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A Randomized Clinical Trial. Cancer 74:2749–2756PubMedCrossRefGoogle Scholar
  126. 119.
    Glimelius B (1993) Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235–240PubMedGoogle Scholar
  127. 120.
    Blijham GH (1997) Should patients with advanced colorectal cancer be treated with chemotherapy? Eur J Cancer 33:815–817PubMedCrossRefGoogle Scholar
  128. 121.
    Kemeny NE (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! In: DeVita V, Hellman S, Rosenberg SA (eds) Important Advanced in Oncology. JB Lippincott, Philadelphia pp 207–227Google Scholar
  129. 122.
    O’Connell MJ (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? No! In: DeVita V, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. J.B. Lippincott, Philadelphia, pp 228–234Google Scholar
  130. 123.
    Goldberg RM, Hatfield AK, O’Connell MJ, Mahoney M, Krook JE (1997) Salvage 5-FU-based chemotherapy (CT) for patients (pts) with advanced colorectal cancer (CRC) who have relapsed following surgical adjuvant (ADJ) CT: A North Central Cancer Treatment Group Trial. Proc Am Soc Clin Oncol 16:271 aGoogle Scholar
  131. 124.
    MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460PubMedCrossRefGoogle Scholar
  132. 125.
    Higgins GA, Humphrey EW, Dwight TW et al. (1986) Preoperative radiation and surgery for cancer of the rectum: Veterans Administration Surgical Oncology Group Trial 11. Cancer 58:352–359PubMedCrossRefGoogle Scholar
  133. 126.
    Gerard A, Buyse M, Norlinger B et al. (1988) Pre-operative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 208:606–614PubMedCrossRefGoogle Scholar
  134. 127.
    Dahl O, Horn A, Morild I et al. (1990) Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Cancer 66:2286–2294PubMedCrossRefGoogle Scholar
  135. 128.
    Stockholm Rectal Cancer Study Group (1990) Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 66:49–55CrossRefGoogle Scholar
  136. 129.
    Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312:1465–1472CrossRefGoogle Scholar
  137. 130.
    Gastrointestinal Tumor Study Group (1986) Survival after post operative combination treatment of rectal cancer. N Engl J Med 315:1294–1295CrossRefGoogle Scholar
  138. 131.
    Balslev I, Pederson M, Teglbjaerg PS et al. (1986) Post-operative radiotherapy in Dukes’ B and C carcinoma of the rectum and rectosigmoid. Cancer 58: 22–28PubMedCrossRefGoogle Scholar
  139. 132.
    Fisher B, Wolmark N, Rockette H et al. (1988) Postoperative adjuvant chemotherapy or radiotherapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 80:21–29PubMedCrossRefGoogle Scholar
  140. 133.
    Treurniet-Donker AD, Van Putten LJ, Wereldsma JC et al. (1991) Postoperative radiation therapy for rectal cancer. Cancer 67:2042–2048PubMedCrossRefGoogle Scholar
  141. 134.
    Pahlman L, Glimelius B (1990) Pre- or post-operative radiotherapy in rectal and recto-sigmoid carcinoma. Ann Surg 211:187–195PubMedCrossRefGoogle Scholar
  142. 135.
    Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987CrossRefGoogle Scholar
  143. 136.
    Holm T, Singnomklao T, Rutqvist LE, Cdermark B (1996) Adjuvant preoperative radiotherapy in patients with rectal carcinoma: adverse effects during long term follow-up of two randomized trials. Cancer 78:968–976PubMedCrossRefGoogle Scholar
  144. 137.
    Frykholm GJ, Glimelius B, Pahlman L (1993) Preoperative or postoperative irradiation in adonocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 36:564–572PubMedCrossRefGoogle Scholar
  145. 138.
    Minsky B (1997) Adjuvant therapy for rectal cancer — a good first step. N Engl J Med 336:1016–1017PubMedCrossRefGoogle Scholar
  146. 139.
    Krook JE, Moertel CG, Gunderson LL et al. (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Eng J Med 324:709–715CrossRefGoogle Scholar
  147. 140.
    Rockette H, Deutsch M, Petrelli N et al. (1994) Effect of postoperative radiation therapy (RTX) when used with adjuvant chemotherapy in Dukes’ B and C rectal cancer: results from NSABP R-02. Proc Am Soc Clin Oncol 13:193Google Scholar
  148. 141.
    Wils J, Wagener DJTh (1992) Combined modality adjuvant treatment of high-risk rectal cancer: a treatment of choice or a choice of treatment? Ann Oncol 3:192–199Google Scholar
  149. 142.
    Gastrointestinal Tumor Study Group (1992) Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 10:549–557Google Scholar
  150. 143.
    O’Connell MJ, Martenson J, Wieand H et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507PubMedCrossRefGoogle Scholar
  151. 144.
    Tepper JE, O’Connell MJ, Petroni GR et al. (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol 15:2030–2039PubMedGoogle Scholar
  152. 145.
    Gunderson LL (1994) Adjuvant therapy for rectal cancer. ASCO Eductational Book, pp 162–170Google Scholar
  153. 146.
    Minsky B, Cohen A, Enker W et al. (1993) Preoperative 5-FU, low dose leucovorin and concurrent radiation therapy for rectal cancer. Proc Am Soc Clin Oncol 12:194Google Scholar
  154. 147.
    Rietmüller G, Schneider-Gädicke E, Schlimok G et al. (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343:1177–1183CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • G. H. Blijham

There are no affiliations available

Personalised recommendations